BIPOLAR II DISORDER
Clinical trials for BIPOLAR II DISORDER explained in plain language.
Never miss a new study
Get alerted when new BIPOLAR II DISORDER trials appear
Sign up with your email to follow new studies for BIPOLAR II DISORDER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Ketamine shows promise for stubborn bipolar depression
Disease control CompletedThis study tested whether regular ketamine infusions could help maintain relief from severe bipolar depression in people who initially responded to the treatment. Forty-one adults with treatment-resistant bipolar depression received flexible-dose ketamine infusions every 2-4 week…
Matched conditions: BIPOLAR II DISORDER
Phase: PHASE2 • Sponsor: Joshua Rosenblat • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
Ketamine shows promise for stubborn bipolar depression in new trial
Disease control CompletedThis study tested whether repeated low-dose ketamine infusions could help people with treatment-resistant bipolar depression. 71 participants who hadn't responded to standard medications received either ketamine or a sedative placebo over two weeks. Researchers measured changes i…
Matched conditions: BIPOLAR II DISORDER
Phase: PHASE2 • Sponsor: Joshua Rosenblat • Aim: Disease control
Last updated Mar 30, 2026 14:29 UTC
-
New pill tested to lift the fog of bipolar depression
Disease control CompletedThis study tested whether a new oral medication called ABBV-932 could safely help reduce depressive symptoms in adults with bipolar I or II disorder. About 160 participants worldwide were randomly assigned to receive either the drug or a placebo pill daily for six weeks. Research…
Matched conditions: BIPOLAR II DISORDER
Phase: PHASE2 • Sponsor: AbbVie • Aim: Disease control
Last updated Mar 27, 2026 12:39 UTC
-
New At-Home calming treatment tested for mental health crises
Symptom relief CompletedThis study tested a medication called BXCL501 to see if it could safely and effectively calm episodes of agitation when used at home by adults with schizophrenia or bipolar disorder. In the second part of the trial, 452 participants used the medication as needed over 12 weeks at …
Matched conditions: BIPOLAR II DISORDER
Phase: PHASE3 • Sponsor: BioXcel Therapeutics Inc • Aim: Symptom relief
Last updated Mar 30, 2026 14:29 UTC